News
SPHRF
0.350
NaN%
--
Starpharma Appoints New Chair and Deputy Chair
TipRanks · 11/06 04:32
Starpharma Shareholders Approve All Six AGM Resolutions
TipRanks · 11/06 04:32
Starpharma Details AGM Transition and Oncology Strategy
TipRanks · 11/06 01:17
Starpharma relocates Melbourne headquarters as dendrimer portfolio advances
TipRanks · 10/23 06:08
Starpharma Secures $3.5 Million R&D Tax Incentive to Support Oncology Pipeline
TipRanks · 10/21 22:19
Starpharma Tightens Grip on Petalion as Majority Owner in FAP-Targeted Cancer Program
TipRanks · 10/21 04:07
Starpharma sets 2026 AGM and outlines board leadership transition
TipRanks · 10/06 03:59
Starpharma Director’s Performance Rights Lapse After Targets Missed
TipRanks · 10/04 22:47
Starpharma Seeks ASX Quotation for 2.68 Million New Shares
TipRanks · 10/04 22:47
Starpharma Reports Lapse of 2.2 Million Performance Rights
TipRanks · 10/04 22:38
Starpharma Reshapes Board Leadership to Back Oncology and Global Growth Push
TipRanks · 10/01 01:58
UBS Group AG Withdraws as Substantial Shareholder in Starpharma
TipRanks · 09/25 08:04
UBS exits substantial holder position in Starpharma
TipRanks · 09/15 08:28
Starpharma sets 2026 AGM date and flags board nomination deadline
TipRanks · 09/15 06:02
UBS Group Ceases to Be Substantial Shareholder in Starpharma
TipRanks · 08/31 09:24
Starpharma Highlights Patient-Focused Dendrimer Strategy in Annual Report
TipRanks · 08/26 01:04
Starpharma Boosts Revenue on Genentech Deal While Deepening R&D Spend
TipRanks · 08/26 00:17
UBS Group AG Drops Below Substantial Holding in Starpharma
TipRanks · 08/19 07:46
Starpharma Director Increases Stake Through Entitlement Offer
TipRanks · 08/13 11:12
Starpharma Director Increases Indirect Shareholding via Entitlement Offer
TipRanks · 08/13 11:12
More
Webull provides a variety of real-time SPHRF stock news. You can receive the latest news about Starpharma Holdings Ltd through multiple platforms. This information may help you make smarter investment decisions.
About SPHRF
Starpharma Holdings Limited is an Australia-based biotechnology company specializing in advancing dendrimer technology. The Company's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The Company's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. It also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The Company has applied its DEP technology to the innovative area of antibody-drug conjugates.